Filing Details
- Accession Number:
- 0001179110-17-003930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-03-06 06:59:38
- Reporting Period:
- 2017-03-02
- Filing Date:
- 2017-03-06
- Accepted Time:
- 2017-03-06 06:59:38
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1578845 | Allergan Plc | AGN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1237253 | Paul Bisaro | Clonshaugh Business And Technology Park, Coolock, Co. Dublin L2 D17 E400 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, Par Value $0.0001 | Disposition | 2017-03-02 | 31,674 | $245.73 | 274,226 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.0001 | Disposition | 2017-03-02 | 8,267 | $246.64 | 265,959 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.0001 | Disposition | 2017-03-02 | 27,688 | $247.63 | 238,271 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.0001 | Disposition | 2017-03-02 | 2,371 | $248.40 | 235,900 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Ordinary Shares, Par Value $0.0001 | 120,000 | Indirect | Paul Bisaro LLC |
Footnotes
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $245.21 to $246.17, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $246.21 to $247.02, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $247.22 to $248.21, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $248.33 to $248.45, inclusive. The sale price reported above represents the weighted average sale price for the reported transaction and has been rounded to the nearest cent.
- Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
Billionaire Hedge Funds
